Last updated: 2026-10-03 23:31:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Psyence Biomedical Ltd (PBM) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $5.23, with a market capitalization of $20.90M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.92 to $28.13. This page covers its latest market performance, valuation, price trends and company information.
$20.90M | |
$5.52 | |
$57,533.44 | |
$1.92 | |
$5.48 | |
74.44K | |
93.38K | |
-- | |
$28.13 | |
$1.92 | |
-- | |
-- |
Psyence Biomedical Ltd (PBM) last closed at $5.48 as of 2026-10-02 23:42:00, unchanged from the previous close of $5.48.
During the latest regular trading session, PBM traded between $1.92 and $57,533.44, with a volume of 74.44K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Psyence Biomedical Ltd (PBM) moved from $5.86 to $5.23, representing a decline of 10.73% ($0.63).
The stock traded between $5.12 and $6.37 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 61.76 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 12.6%
PBM is currently trading at $5.23, placing it 12.6% of the way from its 52-week low of $1.92 to its 52-week high of $28.13. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Psyence Biomedical Ltd (PBM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.